Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer - PubMed (original) (raw)

Conflict of interest statement

Emily Nizialek: Consulting or Advisory Role: AstraZeneca. Jacob E. Berchuck: Honoraria: Digital Science Press. Consulting or Advisory Role: Genome Medical, VetOncoDx. Equity: Genome Medical, VetOncoDx, Cityblock Health (spouse). Employment: Cityblock Health (spouse). Travel, Accommodations, Expenses: Digital Science Press. Patents: Institutional patent filed on methods to detect neuroendocrine prostate cancer through tissue‐informed cell‐free DNA methylation analysis. Pedro C. Barata: Consultant (Institutional): Astellas; Eisai; AVEO Oncology, Janssen, EMD Serono; Dendreon; Pfizer, Seattle Genetics, BMS, Bayer, Guardant Health. Contracted Research (Institutional): AstraZeneca, Merck, AVEO Oncology. Research Grant (Institutional): Blue Earth Diagnostics. Speaker's Bureau (Institutional): Bayer, Caris, Myovant. Rahul R. Aggarwal: Honoraria: Clovis Oncology. Consulting or Advisory Role: Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer. Research Funding: Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst). Rana R. McKay: Consulting or Advisory Role: Aveo, Astellas, Medivation, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera Biosciences, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, Tempus, and Vividion Therapeutics. R. R. M. receives research funding from Tempus, Bayer. Neerja Agarwal: Consulting or Advisory Role: Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Funding to Institution: Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Alan H. Bryce: Funding to Institution: Janssen, AstraZeneca, Gilead. Consulting: Merck, Bayer. Honoraria: Elsevier, Fallon Medica, Horizon CME, PRIME Education, MJH Life Sciences. Patents: Therapeutic Targeting of Cancer Patients wiht NRG1 Rearrangements 15/735,289. Oliver Sartor: Consulting: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics. Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio. Heather H. Cheng: Research Funds to Institution: Clovis Oncology, Color Genomics, Janssen, Medivation, Phosplatin, Sanofi; Consultant: AstraZeneca; Royalties: UpToDate. Nabil Adra: Consulting or Advisory Role: Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Exelixis; Merck; Sanofi. Research Funding: Exelixis (Inst); Genentech (Inst); Merck (Inst). Cora N. Sternberg: Funding, consultancy, advisory: Astellas Pharma/AstraZeneca/Bayer/Genzyme/Gilead/Medscape/Janssen; Merck/MSD/Pfizer/Roche/Impact Pharma/BMS/Sanofi‐Genzyme/UroToday/CCO Clinical, GLC; NCI. Mary‐Ellen Taplin: Consulting or Advisory Role: Janssen, Arcus Bioscience, Roviant, Arvinas, Blue Earth, Clovis, AstraZeneca, Epizyme, Research To Practice, Pfizer, UpToDate. Ajjai S. Alva: Consulting or Advisory Role: AstraZeneca; BMS; Merck; Pfizer. Research Funding: Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol‐Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst). Travel, Accommodations, Expenses: BMS; Merck. Emmanuel S. Antonarakis: Consulting or Advisory Role: Janssen, Astellas, Sanofi, Dendreon, Bayer, BMS, Amgen, ESSA, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis, Eli Lilly. Grant/Research Support: Janssen, J&J, Sanofi, BMS, Pfizer, AstraZeneca, Novartis, Curium, Constellation, ESSA, Celgene, Merck, Bayer, Clovis. Inventions/patents: Coinventor of AR‐V7 technology licensed to Qiagen. The remaining authors declare no conflict of interest.